2024
Rationale and Design of a Phase 2, Double-blind, Placebo-Controlled, Randomized Trial Evaluating AMP Kinase-Activation by Metformin in Focal Segmental Glomerulosclerosis
Barsotti G, Luciano R, Kumar A, Meliambro K, Kakade V, Tokita J, Naik A, Fu J, Peck E, Pell J, Reghuvaran A, Tanvir E, Patel P, Zhang W, Li F, Moeckel G, Perincheri S, Cantley L, Moledina D, Wilson F, He J, Menon M. Rationale and Design of a Phase 2, Double-blind, Placebo-Controlled, Randomized Trial Evaluating AMP Kinase-Activation by Metformin in Focal Segmental Glomerulosclerosis. Kidney International Reports 2024, 9: 1354-1368. PMID: 38707807, PMCID: PMC11068976, DOI: 10.1016/j.ekir.2024.02.006.Peer-Reviewed Original ResearchMinimal change diseaseRandomized controlled trialsSafety of metforminDouble-blindPodocyte injuryAdjunctive therapyPlacebo-controlled randomized controlled trialsPhase III studyPhase II trialPrimary glomerular diseaseFocal segmental glomerulosclerosisEffect of metforminPhase IIPlacebo-controlledPreclinical dataNovel urineChange diseaseTissue markersRandomized trialsSegmental glomerulosclerosisGlomerular diseaseMechanistic biomarkersObservational studyFSGSInexpensive agent
2016
Cyclic‐AMP Regulates Glycogen Synthase Kinase‐3β by a Feed‐Forward Mechanism in Polycystic Kidney Disease
Kakade V, Tao S, Zhou X, Li X, Pandey P, Rajagopal M, Rao R. Cyclic‐AMP Regulates Glycogen Synthase Kinase‐3β by a Feed‐Forward Mechanism in Polycystic Kidney Disease. The FASEB Journal 2016, 30 DOI: 10.1096/fasebj.30.1_supplement.968.28.Peer-Reviewed Original ResearchCRE-binding proteinGlycogen synthase kinase-3βCAMP response elementSynthase kinase-3βSerine/threonine protein kinaseGSK3β expressionKinase-3βCAMP-responsive genesThreonine protein kinasePolycystic kidney diseaseCyst expansionCAMP levelsPotential binding sitesFeed-forward loopInhibition of GSK3βResponsive genesTranscription factorsProtein kinaseFeed-forward mechanismResponse elementGSK3β proteinCell survivalCREB activityGSK3βActive GSK3β